Last €2.92 EUR
Change Today +0.005 / 0.17%
Volume 0.0
As of 2:16 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZEL) Snapshot

Open
€2.83
Previous Close
€2.92
Day High
€2.92
Day Low
€2.83
52 Week High
06/19/14 - €3.07
52 Week Low
09/2/13 - €2.11
Market Cap
649.1M
Average Volume 10 Days
371.5
EPS TTM
--
Shares Outstanding
222.2M
EX-Date
07/15/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZELTIA SA (ZEL)

Related News

No related news articles were found.

zeltia sa (ZEL) Related Businessweek News

No Related Businessweek News Found

zeltia sa (ZEL) Details

Zeltia, S.A. operates in the biopharmaceutical industry and consumer chemical sectors. It researches, develops, produces, and markets various types of bioactive products of marine origin for application in oncology; and products with therapeutic activity based on reducing or silencing gene expression and pharmaceutical derivatives of same in a range of formulations, as well as develops and markets biopharmaceutical applications, diagnosis, and related services. The company’s products include Yondeli, a marketed product for the treatment of ovarian cancer and soft tissue sarcoma; Aplidi, which is in Phase III trials for the treatment of multiple myeloma, as well as in angioimmunoblastic Tcell lymphoma; Zalypsi that is in Phase II trials for the treatment of multiple myeloma; PM1183, which has completed Phase IIb trials for the treatment of platinum-refractory/resistant ovarian cancer; PM060184 that is in Phase I trials for the treatment of various types of tumors; and SYL040012, which is in Phase IIB clinical trials for the treatment of glaucoma. It also develops and markets diagnosis kits. In addition, the company is involved in the manufacture and sale of wood and metal protective and decorative products, paints, and other related products; manufacture and marketing of domestic and industrial insecticides and air fresheners for household use; manufacture and sale of automatic aerosol dispensers under the Copyrmatic brand; and production of products for ecological farming. Further, it provides services for treating and protecting wood, and repairing and preserving structures, as well as insect control and disinfection services. Zeltia, S.A. was founded in 1939 and is headquartered in Madrid, Spain.

Founded in 1939

zeltia sa (ZEL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeltia sa (ZEL) Key Developments

Zeltia S.A. Reports Earnings Results for the First Quarter Ended March 31, 2014

Zeltia S.A. reported earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported a profit attributable to owners of the parent of EUR 16.90 million compared to EUR 15.82 million for the same quarter ended March 31, 2013. Net revenues were EUR 34.21 million, compared to EUR 30.81 million for the same quarter ended March 31, 2013. Net operating profit was EUR 18.08 million compared to EUR 16.46 million for the same quarter ended March 31, 2013.

Zeltia SA Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:00 PM

Zeltia SA Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 04:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: José Luis Fernández Puentes, Director.

Zeltia SA Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014

Zeltia SA Presents at Bank of America Merrill Lynch Health Care Conference, May-13-2014 . Venue: Encore at Wynn Las Vegas, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEL:GR €2.92 EUR +0.005

ZEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEL.
View Industry Companies
 

Industry Analysis

ZEL

Industry Average

Valuation ZEL Industry Range
Price/Earnings 49.2x
Price/Sales 4.3x
Price/Book 9.1x
Price/Cash Flow 51.4x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit www.zeltia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.